Jacqueline Kosecoff - Houlihan Lokey Independent Director
| HLI Stock | USD 190.49 1.75 0.93% |
Director
Dr. Jacqueline B. Kosecoff, Ph.D., is Independent Director of the Company since June 20, 2016. Dr. Kosecoff is a Managing Partner of Moriah Partners, where she works to identify, select, mentor and manage health services and IT companies. Dr. Kosecoff is also a Senior Advisor of Warburg Pincus. From 2002 to 2012, Dr. Kosecoff was a senior executive inside UnitedHealth GroupPacifiCare. Dr. Kosecoff joined UnitedHealth Group as part of its acquisition of PacifiCare Health Systems in 2005. At PacifiCare, Dr. Kosecoff served as Executive Vice President with responsibility for various business segments and, upon joining UnitedHealth Group, Dr. Kosecoff took responsibility for, among other areas, the Medicare Part D business and the consumer health product division serving seniors. In 2007, Dr. Kosecoff was appointed Chief Executive Officer of Prescription Solutions . Prior to joining UnitedHealth GroupPacifiCare, Dr. Kosecoff was founder, President and Chief Operating Officer of Protocare, a firm whose lines of business included the clinical development of drugs, devices, biopharmaceutical and nutritional products, and health services consulting. Dr. Kosecoff served as Professor of Medicine and Public Health at the University of California, Los Angeles from 1975 to 2006. Currently, Dr. Kosecoff sits on the board of directors of these other public companies athenahealth, Inc. Sealed Air Corporation and STERIS Corporation since 2016.
| Age | 71 |
| Tenure | 8 years |
| Address | 10250 Constellation Boulevard, Los Angeles, CA, United States, 90067 |
| Phone | 310 553 8871 |
| Web | https://hl.com |
Jacqueline Kosecoff Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jacqueline Kosecoff against Houlihan Lokey stock is an integral part of due diligence when investing in Houlihan Lokey. Jacqueline Kosecoff insider activity provides valuable insight into whether Houlihan Lokey is net buyers or sellers over its current business cycle. Note, Houlihan Lokey insiders must abide by specific rules, including filing SEC forms every time they buy or sell Houlihan Lokey'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jacqueline Kosecoff over six months ago Disposition of 2807 shares by Jacqueline Kosecoff of TriNet subject to Rule 16b-3 |
Houlihan Lokey Management Efficiency
The company has Return on Asset of 0.1116 % which means that on every $100 spent on assets, it made $0.1116 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1856 %, implying that it generated $0.1856 on every 100 dollars invested. Houlihan Lokey's management efficiency ratios could be used to measure how well Houlihan Lokey manages its routine affairs as well as how well it operates its assets and liabilities. The Houlihan Lokey's current Return On Capital Employed is estimated to increase to 0.15, while Return On Tangible Assets are projected to decrease to 0.15. As of now, Houlihan Lokey's Total Current Assets are increasing as compared to previous years. The Houlihan Lokey's current Intangible Assets is estimated to increase to about 222.1 M, while Total Assets are projected to decrease to under 2.1 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Paul Friedman | Oppenheimer Holdings | 65 | |
| Philip Laskawy | Lazard | 79 | |
| Kathleen Brown | Stifel Financial | 74 | |
| David Peacock | Stifel Financial | 51 | |
| Emily Rafferty | PJT Partners | 71 | |
| Dennis Hersch | PJT Partners | 72 | |
| Sylvia Jay | Lazard | 73 | |
| R Roth | Oppenheimer Holdings | 63 | |
| Kenneth Whitney | PJT Partners | 63 | |
| Adam Berlew | Stifel Financial | 53 | |
| Kendrick Wilson | Evercore Partners | 73 | |
| Simon Robertson | Evercore Partners | 79 | |
| Gail Harris | Evercore Partners | 67 | |
| Willard Overlock | Evercore Partners | 74 | |
| Kenneth Shropshire | Moelis Co | 65 | |
| Iris Knobloch | Lazard | 57 | |
| Michael Brown | Stifel Financial | 74 | |
| Richard Haass | Lazard | 68 | |
| Richard Beattie | Evercore Partners | 81 | |
| Daniel Ludeman | Stifel Financial | 63 | |
| John Allison | Moelis Co | 71 | |
Management Performance
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.11 |
Houlihan Lokey Leadership Team
Elected by the shareholders, the Houlihan Lokey's board of directors comprises two types of representatives: Houlihan Lokey inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Houlihan. The board's role is to monitor Houlihan Lokey's management team and ensure that shareholders' interests are well served. Houlihan Lokey's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Houlihan Lokey's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tom Carlson, Managing Director - Oil and Gas Group | ||
| Jason Abt, Managing Banking | ||
| Ekpedeme Bassey, Independent Director | ||
| Jonathan Guskind, Managing Director - Healthcare Group | ||
| Shane Sealy, Managing Director - Oil & Gas Group | ||
| Cyrus Walker, Independent Director | ||
| Andy Cairns, MD Africa | ||
| Jay Novak, Food Consumer | ||
| Chris Hastings, Managing Director - Capital Markets Group | ||
| Gillian Zucker, Independent Director | ||
| Robert Schriesheim, Independent Director Nominee | ||
| Irwin Gold, Executive Chairman of the Board | ||
| Arik Rashkes, Managing Group | ||
| Jacques Cornet, Investor Professional | ||
| Rainer Hepberger, Managing Team | ||
| Matthew Hudson, Head Group | ||
| Hideto Nishitani, Director | ||
| James Lavelle, MD Industrials | ||
| Burke JD, Managing Group | ||
| James Sutch, Director | ||
| JLindsey Alley, MD CFO | ||
| Andreas Dombret, Independent Chairman of the Board | ||
| Rouzbeh Fazlinejad, Managing Director - Oil and Gas Coverage | ||
| James Scallan, Managing Director | ||
| Matthew Mazzucchi, Financial Group | ||
| Jesse Nichols, Managing Group | ||
| Paul Zuber, Independent Director | ||
| Scott Beiser, Chief Executive Officer, Director | ||
| David Schneider, Managing Director - Industrials Group | ||
| Faiz Vahidy, VP | ||
| Sameer Shamsi, Managing Director and Head of Secondaries in the Private Funds Group | ||
| Chris Godsmark, Managing Director | ||
| Paul Siegert, CoChairman Restructuring | ||
| Spencer Lippman, Managing Group | ||
| Nana Kyei, Managing Group | ||
| Christian Maher, Managing Director | ||
| David Preiser, Co-President Director Nominee | ||
| Michael Collinson, Managing Director | ||
| Charles Yamarone, Chief Officer | ||
| Matthew Niemann, Managing Director | ||
| Walid Khiari, Managing Director - TMT | ||
| Jacqueline Kosecoff, Independent Director | ||
| Keith Skirbe, Managing Sector | ||
| Michael Boone, Director Group | ||
| Christopher JD, General MD | ||
| Scott Adelson, Co-President and Global Co-Head of Corporate Finance, Director | ||
| Robert Wilson, Managing Director | ||
| J Alley, Chief Financial Officer | ||
| Luiz Greca, Managing Director | ||
| Jeffrey Werbalowsky, Senior Director | ||
| Todd Esq, MD Director | ||
| Christian Lunny, Managing Director | ||
| Christopher Crain, General Counsel and Secretary |
Houlihan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Houlihan Lokey a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 12.83 B | ||||
| Shares Outstanding | 53.59 M | ||||
| Shares Owned By Insiders | 0.13 % | ||||
| Shares Owned By Institutions | 99.87 % | ||||
| Number Of Shares Shorted | 633.73 K | ||||
| Price To Earning | 23.98 X |
Currently Active Assets on Macroaxis
When determining whether Houlihan Lokey offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Houlihan Lokey's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Houlihan Lokey Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Houlihan Lokey Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Houlihan Lokey. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Houlihan Stock please use our How to Invest in Houlihan Lokey guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Investment Banking & Brokerage space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Houlihan Lokey. If investors know Houlihan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Houlihan Lokey listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.384 | Dividend Share 2.24 | Earnings Share 4.89 | Revenue Per Share 32.632 | Quarterly Revenue Growth 0.231 |
The market value of Houlihan Lokey is measured differently than its book value, which is the value of Houlihan that is recorded on the company's balance sheet. Investors also form their own opinion of Houlihan Lokey's value that differs from its market value or its book value, called intrinsic value, which is Houlihan Lokey's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Houlihan Lokey's market value can be influenced by many factors that don't directly affect Houlihan Lokey's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Houlihan Lokey's value and its price as these two are different measures arrived at by different means. Investors typically determine if Houlihan Lokey is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Houlihan Lokey's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.